State of the art and future directions in nanomedicine for tuberculosis
Authors:
- Admire DubeADAdmire Dube
- Yolandy LemmerYLYolandy Lemmer
- Rose HayeshiRHRose Hayeshi
- Mohammed BalogunMBMohammed Balogun
- Philip LabuschagnePLPhilip Labuschagne
- Hulda SwaiHSHulda Swai
- Lonji KalomboLKLonji Kalombo
- 8 October 2013
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 10 (12) , 1725-1734
Abstract
Tuberculosis (TB) ranks the second leading cause of death from an infectious disease worldwide. However, treatment of TB is affected by poor patient compliance due to the requirement for daily drug administration, for lengthy periods of time, often with severe drug-induced side effects. Nanomedicines have the potential to improve treatment outcomes by providing therapies with reduced drug doses, administered less frequently, under shortened treatment durations. In this article, we present the pathophysiology of the disease, focusing on pulmonary TB and the characteristics of drugs used in treatment and discuss the application of nanomedicines within this scope. We also discuss new formulation approaches for TB nanomedicines and directions for future research. Nanomedicines have the potential to improve TB treatment outcomes. New approaches such as nanoparticle systems able to impact the immune response of macrophages and deliver drug intracellularly, as well as the use of polymer-drug conjugates for drug delivery, are likely to play an important role in TB nanomedicines in future. However, further research is required before TB nanomedicines can be translated to the clinic.Keywords
This publication has 54 references indexed in Scilit:
- Keto-Mycolic Acid-Dependent Pellicle Formation Confers Tolerance to Drug-Sensitive Mycobacterium tuberculosismBio, 2013
- Emergence and Spread of Extensively and Totally Drug-Resistant Tuberculosis, South AfricaEmerging Infectious Diseases, 2013
- Targeted Intracellular Delivery of Antituberculosis Drugs to Mycobacterium tuberculosis-Infected Macrophages via Functionalized Mesoporous Silica NanoparticlesAntimicrobial Agents and Chemotherapy, 2012
- Janus-faced liposomes enhance antimicrobial innate immune response in Mycobacterium tuberculosis infectionProceedings of the National Academy of Sciences, 2012
- Pharmacokinetic Mismatch of Tuberculosis DrugsAntimicrobial Agents and Chemotherapy, 2012
- Tuberculosis in Dr Granville's mummy: a molecular re-examination of the earliest known Egyptian mummy to be scientifically examined and given a medical diagnosisProceedings Of The Royal Society B-Biological Sciences, 2009
- Foamy macrophages and the progression of the human tuberculosis granulomaNature Immunology, 2009
- Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug‐tolerant bacteriaMolecular Microbiology, 2008
- Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent miceProceedings of the National Academy of Sciences, 2007
- Novel Conjugate of Moxifloxacin and Carboxymethylated Glucan with Enhanced Activity againstMycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2006